Berlin - 18 October 2006. The Berlin based Biotech company MOLOGEN announced today, that the basic patent for MIDGE(TM)-TH1 technology has become legally binding in Europe. The patent is valid until 2020. After the patent was granted in December 2005, competitors were allowed to file formal objection within a period of nine month. This period has now expired, and an effective legal protection of the patent in Europe has come into force.
